TCR2 Therapeutics (NASDAQ: TCRR) recently received a number of ratings updates from brokerages and research firms:

• 3/24/2023 – TCR2 Therapeutics was downgraded by analysts at Mizuho from a "buy" rating to a "neutral" rating. They now have a $1.72 price target on the stock, down previously from $20.00.
• 3/23/2023 – TCR2 Therapeutics had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $1.68 price target on the stock, down previously from $2.18.
• 3/23/2023 – TCR2 Therapeutics had its "hold" rating reaffirmed by analysts at EF Hutton Acquisition Co. I. They now have a $2.00 price target on the stock.
• 3/9/2023 – TCR2 Therapeutics was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $3.00 price target on the stock, down previously from $18.00.
• 3/7/2023 – TCR2 Therapeutics was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.
• 3/7/2023 – TCR2 Therapeutics was downgraded by analysts at Truist Financial Co. from a "buy" rating to a "hold" rating. They now have a $3.00 price target on the stock, down previously from $8.00.

TCR2 Therapeutics Stock Up 5.6 %

Shares of NASDAQ:TCRR opened at $1.50 on Monday. The company has a market capitalization of $57.99 million, a price-to-earnings ratio of -0.38 and a beta of 1.90. TCR2 Therapeutics Inc. has a 52 week low of $0.82 and a 52 week high of $3.88. The firm has a 50 day moving average of $1.36 and a 200 day moving average of $1.43.

Hedge Funds Weigh In On TCR2 Therapeutics

A number of large investors have recently made changes to their positions in TCRR. Tang Capital Management LLC grew its holdings in shares of TCR2 Therapeutics by 2.7% during the third quarter. Tang Capital Management LLC now owns 3,741,606 shares of the company's stock valued at $6,735,000 after buying an additional 100,000 shares during the last quarter. BlackRock Inc. grew its holdings in shares of TCR2 Therapeutics by 5.5% during the first quarter. BlackRock Inc. now owns 2,532,916 shares of the company's stock valued at $6,991,000 after buying an additional 131,171 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of TCR2 Therapeutics by 61.7% during the first quarter. Renaissance Technologies LLC now owns 1,442,600 shares of the company's stock valued at $3,982,000 after buying an additional 550,700 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of TCR2 Therapeutics by 7.4% during the third quarter. Vanguard Group Inc. now owns 1,433,425 shares of the company's stock valued at $2,581,000 after buying an additional 99,066 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of TCR2 Therapeutics by 1.5% during the first quarter. State Street Corp now owns 523,157 shares of the company's stock valued at $1,444,000 after buying an additional 7,968 shares during the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

TCR2 Therapeutics, Inc is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development.

See Also

• Get a free copy of the StockNews.com research report on TCR2 Therapeutics (TCRR)
• MarketBeat Week in Review – 3/20 – 3/24
• Dividend King Genuine Parts Company Upgraded On Profit Guidance
• The Bottom Is In For Accenture
• 11 Best Consumer Discretionary Stocks of 2023
• 5 Best Dividend Capture Stocks

Receive News & Ratings for TCR2 Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TCR2 Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.